Price movement over the last 24 hours
Aspen Aerogels Inc vs Koninklijke Philips NV — how do they compare? Aspen Aerogels Inc trades at $5.25 (market cap $427.65M), while Koninklijke Philips NV trades at $27.4 (market cap $26.63B). The key difference: Koninklijke Philips NV is far larger — about 62.3× Aspen Aerogels Inc's market cap, and Koninklijke Philips NV pays a 3.7% dividend while Aspen Aerogels Inc pays none. Which is the better fit depends on your goals.
| ASPN | PHG | |
|---|---|---|
Market Cap | $427.65M | $26.63B |
Sector | Technology | Health |
52-Week High | $8.82 | $32.91 |
52-Week Low | $2.57 | $24.03 |
Enterprise Value | $382.60M | $32.90B |
Dividend Yield | — | 3.7% |
Signals from Pluang's Aura AI — not financial advice
ASPN trades at $5.16, down 1.53% on the day, with a bearish technical signal despite oversold RSI readings. The company reported a Q1 2026 loss of $0.28 per share, missing estimates, but revenue beat expectations. Recent news includes a 2025 Supplier of the Year award from General Motors and the staged restart of its East Providence facility. Financials show significant net losses but improving cash flow trends into 2026.
Outlook remains challenging with persistent losses and negative margins, though analyst consensus is strongly bullish (83% buy ratings). Key risks include execution on facility restarts and EV demand volatility. The stock offers high-risk growth potential if operational improvements and electrification trends accelerate profitability.
Royal Philips (PHG) trades at $27.40, up 0.51% today, with a bullish technical signal despite mixed moving averages. The company shows improving fundamentals with net income turning positive to $895 million in 2025 after previous losses, supported by strong operational cash flow of $1.17 billion. Recent FDA clearances for AI-powered medical devices and strategic healthcare partnerships highlight growth initiatives. Analyst consensus leans neutral with 40.9% buy ratings amid stable revenue around $17.8 billion.
PHG presents a recovery story with margin expansion and AI innovation driving upside potential, though execution risks and debt levels near 25% of assets warrant caution. The stock's 24.1 P/E appears reasonable if earnings growth sustains, but investors should monitor competitive pressures in healthcare technology and macroeconomic impacts on capital spending.
Trailing returns across standard periods
Latest headlines on both assets
Aspen Aerogels is an aerogel technology company that designs high-performance insulation. Its products are used in energy infrastructure and electric vehicles to provide thermal management and fire protection.
Read more on ASPN →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →